Arrowhead Pharmaceuticals Cash Flow Statement
NASDAQ: ARWRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Arrowhead Pharmaceuticals free cash flow
In fiscal 2025, Arrowhead Pharmaceuticals generated $179.6 million of operating cash flow and spent $22.7 million on capital expenditures. That left free cash flow of $156.9 million, a free-cash-flow margin of 18.9% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Arrowhead Pharmaceuticals cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-09-30 | FY 20242024-09-30 | FY 20232023-09-30 | FY 20222022-09-30 | FY 20212021-09-30 | FY 20202020-09-30 | FY 20192019-09-30 | FY 20182018-09-30 | FY 20172017-09-30 | FY 20162016-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 30.11M | -609.69M | -209.28M | -176.49M | -140.85M | -84.55M | 67.97M | -54.45M | -34.38M | -81.72M |
| Net Income growth (YoY) | — | — | — | — | — | -224.39% | — | — | — | — |
| Depreciation & Amortization | 22.20M | 16.90M | 10.70M | 8.70M | 6.60M | 4.20M | 2.70M | 3.00M | 2.99M | 3.26M |
| Stock-Based Compensation | 63.37M | 73.97M | 78.13M | 120.89M | 76.67M | 43.38M | 12.39M | 8.45M | 7.89M | 11.60M |
| Change in Working Capital | -16.72M | -9.27M | -83.17M | -129.47M | 215.95M | -64.19M | 84.71M | -6.89M | -805.05K | 6.59M |
| Operating Cash Flow | 179.55M | -462.85M | -153.89M | -136.13M | 171.31M | -95.80M | 173.03M | -47.22M | -23.94M | -64.43M |
| Capital Expenditures | -22.67M | -141.47M | -176.74M | -52.78M | -23.57M | -11.95M | -12.00M | -1.42M | -7.92M | -3.86M |
| Investing Cash Flow | -129.29M | -420.07M | -96.16M | -5.42M | -141.68M | -240.78M | -47.75M | -7.43M | -48.64M | 13.45M |
| Financing Cash Flow | 74.01M | 870.52M | 253.05M | 65.19M | 11.30M | 257.95M | 66.38M | 59.95M | 12.06M | 55.13M |
| Net Change in Cash | 124.26M | -12.40M | 3.01M | -76.36M | 40.85M | -78.22M | 191.67M | 5.29M | -60.53M | 4.15M |
| Free Cash Flow | 156.89M | -604.32M | -330.63M | -188.91M | 147.75M | -107.75M | 161.03M | -48.64M | -31.86M | -68.29M |
This table shows 10 annual periods of Arrowhead Pharmaceuticals's cash flow statement, from FY 2025 back to FY 2016, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ARWR's reporting calendar. What is a cash flow statement?